Role of microbiota short-chain fatty acids in the pathogenesis of autoimmune diseases

There is emerging evidence that microbiota and its metabolites play an important role in helath and diseases. In this regard, gut microbiota has been found as a crucial component that influences immune responses as well as immune-related disorders such as autoimmune diseases. Gut bacterial dysbiosis has been shown to cause disease and altered microbiota metabolite synthesis, leading to immunological and metabolic dysregulation. Of note, microbiota in the gut produce short-chain fatty acids (SCFAs) such as acetate, butyrate, and propionate, and remodeling in these microbiota metabolites has been linked to the pathophysiology of a number of autoimmune disorders such as type 1 diabetes, multiple sclerosis, inflammatory bowel disease, rheumatoid arthritis, celiac disease, and systemic lupus erythematosus. In this review, we will address the most recent findings from the most noteworthy studies investigating the impact of microbiota SCFAs on various autoimmune diseases.

Automated summary

Emerging evidence suggests that microbiota and its metabolites, particularly gut microbiota, play a crucial role in immune responses and autoimmune diseases. Gut bacterial dysbiosis can lead to disease and altered microbiota metabolite synthesis, causing immunological and metabolic dysregulation. Among these metabolites, short-chain fatty acids (SCFAs) produced by gut microbiota have been linked to the pathophysiology of various autoimmune disorders. This review focuses on recent findings regarding the impact of microbiota SCFAs on autoimmune diseases.